Posts Tagged ‘cell and gene therapy’
Best Leukopak Suppliers for Cell Therapy in 2026: Pricing, Quality, and Turnaround Compared
Introduction When it comes to sourcing leukopaks for cell therapy or research, product quality is only half the story. Procurement delays, unanswered inquiries, and limited visibility can stall entire workflows. In 2026, speed and communication matter just as much as purity and yield. To help researchers, process developers, and procurement teams choose confidently, we reviewed…
For More InformationThe Donors Powering Breakthroughs in Maternal and Infant Health
Become a Donor 📞 Call or Text (916) 350-0714 Every great discovery begins with a volunteer. At CGT Global, maternal blood donors are at the heart of pregnancy and infant health research. Their contributions help scientists understand how life begins, how the body adapts during pregnancy, and how to prevent complications that still threaten mothers and…
For More InformationScaling Cell & Gene Therapy Development: How CGT Global Supports Research, Clinical Trials, and Commercialization
By Joanna Wirkus, PhD From RUO to cGMP, CGT Global delivers quality, consistency, and regulatory readiness to help researchers advance therapies from discovery to patients. Executive Summary CGT Global accelerates cell and gene therapy development from discovery to commercialization. By providing rapid and reliable access to high-quality RUO and cGMP-certified materials and operating FDA- and CLIA-certified…
For More InformationMeet CGT Global’s Scientific Team: Vanessa Murillo – Supervisor, Client Scientific Associate Team
October 08, 2025 Written by: Joanna Wirkus, PhD At CGT Global, advancing scientific discoveries worldwide by delivering high-quality biospecimens starts with providing exceptional service to our clients. Today, we’re highlighting how this happens by speaking with Vanessa Murillo, a core member and leader of CGT Global’s Client Scientific Associate team. Vanessa is a Client Scientific…
For More Information5 Green Flags the FDA Looks for in CGT CMC and How to Get Them
Roughly 50 to 75 percent of FDA rejections in cell and gene therapy are not about safety or efficacy. They are due to CMC and manufacturing deficiencies. In short, most programs do not fail because the science does not work. They fail because the manufacturing story is not strong enough. (Sources: Jefferies analysis of FDA…
For More InformationBaby KJ Makes Headlines as the First Infant to Receive Personalized CRISPR Gene Editing Therapy
Written by Joanna Wirkus, PhD May 15, 2025, NPR ’s Science Friday spotlighted Baby KJ, the first infant to receive a personalized CRISPR-based gene editing treatment. The segment explored the groundbreaking therapy, the condition it aims to treat, and the collaborative effort behind this historic milestone. Here’s a summary of the key points from the…
For More InformationAlzheimer’s & Neurodegenerative Disease: A Global Challenge
Written by CGT Global Cell & Gene Therapy Is Shifting the Paradigm Recent CGT innovations are upending traditional models and opening new paths to treat or even reverse Alzheimer’s progression: 1. AAV-Based Gene Therapy (LX1001) 2. CRISPR-Engineered Microglia 3. Behavior-Reprogramming Gene Therapy (UC San Diego) 4. Stem Cells & MSC Therapies 5. iPSC TriCulture Models…
For More InformationCGT Global Appoints Dr. Andrew Branagan to Board of Advisors, Expanding Cell and Gene Therapy Expertise
CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today announced the appointment of Andrew Robert Branagan, MD, PhD, to its Board of Advisors. Dr. Branagan brings extensive expertise in hematologic malignancies, immunology, and the development of novel therapeutic strategies, including cellular therapies. This press release features…
For More InformationMeet CGT Global’s Scientific Team: Bryan Pulling – Laboratory Operations Manager
Written by Joanna Wirkus, PhD Every day at CGT Global, our experienced team collaborates to deliver high quality cells to scientists around the world. Success starts with the strength of our team and the dedication of the people who power it. In this edition of Meet the Scientific Team, we’re proud to spotlight Bryan Pulling…
For More InformationFast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilities
By: Joanna Wirkus Despite exponential progress in the field of biology, inherited and preventable diseases continue to burden billions of people worldwide. Bridging the gap between laboratory discoveries and transformative clinical therapies remains a significant challenge, , and an urgent opportunity. High-quality biospecimens are foundational to this effort, enabling the advancement of cell and gene…
For More Information